Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

7(63.6%)

N/A

2(18.2%)

Phase 2

1(9.1%)

Phase 3

1(9.1%)

11Total

Phase 1(7)

N/A(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06668896Phase 1Not Yet Recruiting

Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert

Role: lead

NCT06127199Not ApplicableRecruiting

Contraceptive Efficacy Study of Ovaprene

Role: lead

NCT05752526Phase 1Completed

A Study of Diclofenac Gel in Women With Primary Dysmenorrhea

Role: lead

NCT05765487Phase 1Completed

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

Role: lead

NCT05367973Phase 1Completed

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

Role: lead

NCT05378269Phase 1Completed

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

Role: lead

NCT05418426Phase 1Completed

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Role: lead

NCT04370548Phase 3Completed

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

Role: lead

NCT03598088Not ApplicableCompleted

Safety and Acceptability Study of a Non-Hormonal Ring

Role: lead

NCT05354050Phase 1Completed

Pharmacokinetic Study of DARE-BV1

Role: lead

NCT04948151Phase 2Unknown

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Role: collaborator

All 11 trials loaded